Search

everythinglearnresearchcommunity

for

Search:↓

RC48 shows promise for treating certain advanced cancers, but more research is needed.

New oral treatments for adult hair loss show promise, especially JAK inhibitors, with mild side effects.

Combining DEB-BACE with chemotherapy is more effective and has fewer side effects than chemotherapy alone for treating unresectable lung squamous cell carcinoma.

Patients with rheumatoid arthritis using tofacitinib had more serious side effects than those with alopecia areata.

Comprehensive screening for infections is crucial before starting JAK inhibitors in alopecia areata patients.

Tofacitinib is a promising and safe treatment for moderate to severe alopecia areata.

Tofacitinib works well for treating alopecia areata, especially when combined with corticosteroids, but is less effective if the disease has lasted over 2 years.

Ritlecitinib improves hair regrowth satisfaction in alopecia areata patients.

Tofacitinib is an effective and safe treatment for alopecia areata.

Baricitinib shows promise in improving frontal fibrosing alopecia symptoms.

JAK inhibitors may help treat alopecia areata by reversing hair loss.

TYK2 inhibition may help treat alopecia areata by promoting hair growth and reducing immune response.

Repurposing existing drugs and using micronutrients may effectively target cancer stem cells and improve cancer treatment.

The combination of gemcitabine and vinorelbine is effective and safe for treating elderly patients with advanced breast cancer previously treated with anthracyclines and taxanes.

Personalized sonidegib dosing can effectively treat Gorlin-Goltz syndrome with fewer side effects.

Tofacitinib was more effective than apremilast in treating hair loss in a mouse model of alopecia areata.

Sorafenib can cause facial acne-like eruptions, which improve after reducing the dose or stopping the drug.

Imuvert can prevent some chemotherapy-induced hair loss.

Trastuzumab deruxtecan is effective for advanced breast cancer but has side effects like nausea and fatigue.

Modern skin cancer treatments can cause skin side effects and hair loss, affecting patients' quality of life.

Sonidegib and vismodegib are similarly effective for advanced basal cell carcinoma, but sonidegib might have a slightly better safety profile.

Low-dose sorafenib can cause severe facial acne, treatable with topical medication.

Targeting Keratin 17 may help overcome cancer therapy resistance.

Abatacept may help some people with alopecia areata regrow hair.

Baicalin may help treat severe drug-induced skin reactions.

Pembrolizumab can cause unusual eyelash growth, but it may still be worth continuing if cancer treatment is effective.

Dalpiciclib is the safest and most satisfying CDK4/6 inhibitor for advanced breast cancer patients in China.

JAK inhibitors may effectively treat lichen planopilaris and frontal fibrosing alopecia with minimal side effects.

Tofacitinib is effective and safe for treating alopecia areata with a good drug survival rate.

Certain herbal compounds, especially from bitter melon, can inhibit cancer growth and promote hair growth by blocking PAK1.